Victoza is the brand name of liraglutide, a once-daily GLP-1 receptor agonist used with diet and exercise to improve glycemic control in type 2 diabetes and to reduce major adverse cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. U.S. initial approval was in 2010.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05794581 |
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes |
COMPLETED | PHASE1 |
| NCT05029076 |
Human Bioequivalence Test of Liraglutide Injection |
COMPLETED | PHASE1 |
| NCT02777073 |
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes |
COMPLETED | NA |
| NCT02059564 |
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus |
UNKNOWN | PHASE1 |
| NCT01931982 |
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes. |
COMPLETED | PHASE4 |
